Extranodal Nk T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Extranodal Nk T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type [Phase 2]
Phase 2 clinical trial of IMC-001 in subjects with relapsed or refractory extranodal NK/T-cell lymphoma, nasal type; the study is currently …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) [Phase 1, Phase 2]
An update on a Phase 1/Phase 2 trial of MEPL-G (mitoxantrone liposome, etoposide, dexamethasone, pegaspargase, and golodocitinib) for extran…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating tislelizumab plus zeprumetostat for relapsed or refractory NK/T-cell lymphoma is listed as not yet rec…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma [Phase 2]
A Phase 2 trial compares adding golidocitinib to a P-GemOx regimen plus a PD-1 inhibitor against P-GemOx plus a PD-1 inhibitor as first-line…
-
CLINICAL_TRIALS research · 2025-05-01Clinical Trial Update: A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL. [Phase 3]
A Phase 3 trial comparing the P-GEMD regimen with the P-Gemox regimen in untreated early-stage or advanced extranodal NK/T-cell lymphoma, st…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-04-29Clinical Trial Update: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies [Phase 1]
This clinical trial update describes a Phase 1 dose-escalation and dose-expansion study of anti-CD7 allogeneic CAR T-cells (WU-CART-007) in …
-
CLINICAL_TRIALS research · 2025-02-13Clinical Trial Update: Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma [Phase 2]
This entry reports a Phase 2 clinical trial evaluating a combination of sintilimab, pegaspagase, and GemOx (gemcitabine and oxaliplatin) for…
-
CLINICAL_TRIALS research · 2018-07-26Clinical Trial Update: Tofacitinib Combined With Chidamide in R/R ENKTCL [Phase 2]
A Phase 2 clinical trial is evaluating the combination of tofacitinib with chidamide in relapsed/refractory Extranodal NK/T-cell lymphoma; c…
-
CLINICAL_TRIALS research · 2013-12-24Clinical Trial Update: MESA Treatment for NK/T Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is exploring the MESA treatment regimen for extranodal NK/T-cell lymphoma, with the current trial status listed as …
-
CLINICAL_TRIALS research · 2012-05-07Clinical Trial Update: Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP [Phase 3]
A Phase 3 clinical trial evaluating adding alemtuzumab to dose-dense CHOP for peripheral T-cell lymphomas, including angioimmunoblastic T-ce…